Category: Moderna
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.
-
New COVID-19 vaccine patent suit: BioNTech v. Moderna
BioNTech has sued Moderna in the United States District Court for the District of Delaware, alleging that the defendant’s most profitable vaccine mNexspike infringes on its key RNA technology.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technologyÂ
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.